NGM Bio Announces Closing of Tender Offer
April 05, 2024 09:19 ET
|
NGM Biopharmaceuticals, Inc.
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
March 19, 2024 17:30 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
March 11, 2024 16:05 ET
|
NGM Biopharmaceuticals, Inc.
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with...
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
February 26, 2024 09:03 ET
|
NGM Biopharmaceuticals, Inc.
NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding...
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
February 20, 2024 16:01 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
January 17, 2024 16:47 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need
January 09, 2024 08:00 ET
|
NGM Biopharmaceuticals, Inc.
Encouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS colorectal cancer (CRC), in ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4...
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
November 13, 2023 09:45 ET
|
NGM Biopharmaceuticals, Inc.
--As previously reported, the ALPINE 4 study met its primary endpoint, with aldafermin 3 mg demonstrating a statistically significant reduction in Enhanced Liver Fibrosis (ELF) score compared to...
NGM Bio to Participate in Upcoming Investor Conferences
November 07, 2023 16:05 ET
|
NGM Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative...
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
November 02, 2023 16:01 ET
|
NGM Biopharmaceuticals, Inc.
--Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023-- --Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438-- ...